A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer

Enzalutamide (ENZA), a second-generation androgen receptor antagonist, has significantly increased progression-free and overall survival of patients with metastatic prostate cancer (PCa). However, resistance remains a prominent obstacle in treatment. Utilizing a kinome-wide CRISPR-Cas9 knockout scre...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jinghui, Zhao, Yue, He, Daheng, Jones, Katelyn M., Tang, Shan, Allison, Derek B., Zhang, Yanquan, Chen, Jing, Zhang, Qiongsi, Wang, Xinyi, Li, Chaohao, Wang, Chi, Li, Lang, Liu, Xiaoqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140619/
https://www.ncbi.nlm.nih.gov/pubmed/37075701
http://dx.doi.org/10.1016/j.xcrm.2023.101015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140619/
https://www.ncbi.nlm.nih.gov/pubmed/37075701
http://dx.doi.org/10.1016/j.xcrm.2023.101015

Ejemplares similares